Moderna, Merck Revive mRNA Hopes With Melanoma Success
A personalized vaccine developed by Moderna and Merck reduced the recurrence of melanoma in a large, late-stage trial, raising expectations for treating the deadliest form of skin cancer and showing the promise of the embattled mRNA technology. Madison Muller explains (Source: Bloomberg)
We haven't written up this one. Bloomberg has the full story — the link below goes straight to it.
This story
This is one outlet's version. Read the fullest account.
- Moderna and Merck shares surge after melanoma vaccine success financialpost.com
